EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Development of a Recombineering System for the Acetogen Eubacterium limosum with Cas9 Counterselection for Markerless Genome Engineering

Patrick A Sanford, Benjamin M Woolston iD

ACS Synthetic Biology · 16.08.2024 · 13 (8) · 2505-2514

DOI: 10.1021/acssynbio.4c00253 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Synthetic Biology, online erschienen am 21.07.2024. Verfasst von Patrick A Sanford und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Engineering, Northeastern University, 360 Huntington Avenue, 223 Cullinane, Boston, Massachusetts 02115, United States. Hauptthemen laut MEDLINE: Eubacterium, CRISPR-Cas Systems. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Northeastern University, Advanced Research Projects Agency - Energy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Eubacterium limosum is a Clostridial acetogen that efficiently utilizes a wide range of single-carbon substrates and contributes to metabolism of health-associated compounds in the human gut microbiota. These traits have led to interest in developing it as a platform for sustainable CO2-based biofuel production to combat carbon emissions, and for exploring the importance of the microbiota in human health. However, synthetic biology and metabolic engineering in E. limosum have been hindered by the inability to rapidly make precise genomic modifications. Here, we screened a diverse library of recombinase proteins to develop a highly efficient oligonucleotide-based recombineering system based on the viral recombinase RecT. Following optimization, the system is capable of catalyzing ssDNA recombination at an efficiency of up to 2%. Addition of a Cas9 counterselection system eliminated unrecombined cells, with up to 100% of viable cells encoding the desired mutation, enabling creation of genomic point mutations in a scarless and markerless manner. We deployed this system to create a clean knockout of the extracellular polymeric substance (EPS) gene cluster, generating a strain incapable of biofilm formation. This approach is rapid and simple, not requiring laborious homology arm cloning, and can readily be retargeted to almost any genomic locus. This work overcomes a major bottleneck in E. limosum genetic engineering by enabling precise genomic modifications, and provides both a roadmap and associated recombinase plasmid library for developing similar systems in other Clostridia of interest.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EubacteriumCRISPR-Cas SystemsMetabolic EngineeringRecombination, GeneticGenome, BacterialCRISPR-Associated Protein 9RecombinasesGenetic EngineeringGene EditingMultigene Family

Stichwörter der Autor:innen

C1 metabolismclostridial metabolic engineeringgas fermentationgenome engineeringgut microbiomerecombineering

Substanzen

CRISPR-Associated Protein 9Recombinases

Autor:innen und Institutionen

  • Department of Chemical Engineering, Northeastern University, 360 Huntington Avenue, 223 Cullinane, Boston, Massachusetts 02115, United States.

ORCID-Profile: Benjamin M Woolston

Förderung

  • Northeastern University
  • Advanced Research Projects Agency - Energy

Zitieren

APA

Sanford, P. A., & Woolston, B. M. (2024). Development of a Recombineering System for the Acetogen Eubacterium limosum with Cas9 Counterselection for Markerless Genome Engineering. ACS Synthetic Biology, 13(8), 2505-2514. https://doi.org/10.1021/acssynbio.4c00253

Vancouver

Sanford PA, Woolston BM. Development of a Recombineering System for the Acetogen Eubacterium limosum with Cas9 Counterselection for Markerless Genome Engineering. ACS Synthetic Biology. 2024;13(8):2505-2514. doi:10.1021/acssynbio.4c00253

BibTeX
@article{Sanford2024,
  author = {Sanford, Patrick A and Woolston, Benjamin M},
  title = {Development of a Recombineering System for the Acetogen Eubacterium limosum with Cas9 Counterselection for Markerless Genome Engineering},
  journal = {ACS Synthetic Biology},
  year = {2024},
  volume = {13},
  number = {8},
  pages = {2505--2514},
  doi = {10.1021/acssynbio.4c00253}
}
Kostenlos starten →